Who Should Not Take HRT?

Hormone therapy is safe for most healthy women who start it under 60 or within ten years of menopause, and it is the wrong choice for some. A short list of conditions rules out systemic estrogen. Other conditions change the form or the dose. Women who can’t take systemic estrogen can often use low-dose vaginal estrogen for dryness and bladder symptoms or use non-hormonal prescriptions for hot flashes.

It is general information. The decision is made with a clinician who knows your history.

Conditions that generally rule out systemic hormone therapy

Systemic means estrogen that reaches the whole body: pills, patches, gels, sprays, the systemic ring. These are the situations where guidelines and product labelling advise against it:

• Current or past breast cancer. For most women with a breast cancer history, systemic estrogen is avoided because of the risk of recurrence. There are exceptions discussed between a woman, her oncologist and a menopause clinician, but the default is no.
• Other estrogen-sensitive cancers, such as endometrial cancer that hasn’t been fully treated.
• Unexplained vaginal bleeding. Not a permanent bar, but it must be investigated and explained first; see bleeding in perimenopause and after.
• A recent blood clot in a leg or lung, a stroke or a heart attack, or active heart disease.
• A known inherited clotting disorder such as factor V Leiden with a clot history.
• Active liver disease.
• Pregnancy, which is still possible in perimenopause; see pregnancy during perimenopause.

If one of these is you, skip to the two sections at the end: what you can still use, and the non-hormonal options.

Conditions that change the form

These conditions do not always rule out treatment. The form often matters:

Situation	What it means	Usual approach
A past clot with a clear cause (surgery, pregnancy, a long flight)	Oral estrogen is out; the clot risk of transdermal estradiol is much lower	Transdermal estradiol considered with specialist input
Migraine with aura	Oral estrogen raises stroke risk in this group	Transdermal estradiol at a steady dose; often helps migraines by removing hormone swings
Migraine without aura	Not a contraindication	Any form; transdermal often preferred
High blood pressure	Must be controlled first	Transdermal estradiol once controlled
High triglycerides	Oral estrogen raises them	Transdermal
Gallbladder disease	Oral estrogen raises gallbladder risk	Transdermal
Obesity or smoking	Higher baseline clot risk	Transdermal; stopping smoking matters more than the hormones
Family history of breast cancer	Not a contraindication in itself	Individual discussion of risk; estrogen-alone and micronised progesterone regimens carry the least breast risk
BRCA mutation carrier	Depends on surgery history and oncology advice	Specialist decision; often acceptable after risk-reducing surgery
History of endometriosis	Estrogen can reactivate it	Combined regimen even after hysterectomy; monitored
Fibroids	May grow a little on estrogen	Monitored; not a bar
Diabetes	Not a contraindication; transdermal has less metabolic effect	Transdermal; blood sugar monitored
Over 60, or more than 10 years past menopause, starting fresh	Benefit-risk balance less favourable than starting earlier	Individual decision; transdermal, lowest effective dose; local vaginal estrogen fine regardless
Liver disease that’s stable	Oral estrogen is processed by the liver	Transdermal

Patch vs pill vs gel explains why the skin route is safer for most of these, and heart risk and hormone therapy covers the cardiovascular evidence and the FDA’s 2025 labelling change.

Things that are not reasons to refuse HRT

Women are still told no for reasons the evidence doesn’t support:

• “You’re too young for menopause.” Perimenopausal symptoms in the 40s are the commonest reason to start treatment, and premature menopause before 40 is a reason to start, not to wait.
• “Your hormone levels are normal.” Treatment is decided on symptoms; see hormone testing.
• “HRT causes breast cancer.” The risk picture is more specific than that: a small increase with some combined regimens used for several years, less with estrogen alone and with micronised progesterone, and the FDA began removing its broad boxed warnings in November 2025. See the BHRT guide safety section.
• “You’ve been on it five years, time to stop.” There’s no fixed stopping age; see how long you can stay on HRT.
• A family history of breast cancer on its own.
• Being overweight or having high blood pressure, once controlled: reasons for transdermal, not for no.

What you can still use if systemic estrogen is out

Low-dose vaginal estrogen. For dryness, painful sex and urinary symptoms and recurrent infections, low-dose vaginal estrogen acts on the tissue it touches and very little reaches the bloodstream. Guidelines regard it as acceptable for most women in the groups above, including many breast cancer survivors with their oncologist’s agreement, particularly those not on aromatase inhibitors. Vaginal DHEA and oral ospemifene are alternatives for painful sex.

Non-hormonal treatments for hot flashes and night sweats:

• Fezolinetant, FDA-approved in 2023, blocks the brain signal behind flashes; not a hormone; needs liver-enzyme tests in the first months.
• Low-dose paroxetine, FDA-approved for flashes; venlafaxine and other SSRIs/SNRIs used off-label with similar effect, and they help mood. Some SSRIs interact with tamoxifen, so the choice matters after breast cancer.
• Gabapentin, especially for night-time flashes and sleep.
• Oxybutynin, which reduces flashes and sweating.

Cognitive behavioural therapy and clinical hypnosis, both recommended by The Menopause Society for hot flashes; see CBT for menopause.

For other symptoms: CBT for insomnia, treatment of depression and anxiety, strength training, vitamin D and sometimes bone medication for bone density, along with lifestyle changes that help regardless of hormones.

How this is decided at Golden Leaf Health

The first visit reviews these options against your history. If systemic hormone therapy isn’t right for you, the clinician says so and builds a plan from the alternatives above. Those options can also be prescribed by video. If you’ve been refused hormone therapy elsewhere for one of the reasons in the “not reasons” section, bring the details. Book a first visit if you’d like your situation reviewed.

Sources: The Menopause Society, 2022 hormone therapy position statement; ACOG, Hormone therapy for menopause; FDA, November 2025 announcement on menopausal hormone therapy labelling; Mayo Clinic, Hormone therapy: is it right for you?.